SynthesisMedicine2018
Terlipressin for the treatment of acute variceal bleeding: A systematic review and meta-analysis of randomized controlled trials.
Synthesis in Medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Terlipressin Versus Somatostatin/Octreotide on Effect of Renal Function in Cirrhotic Patients With Acute Gastrointestinal Hemorrhage (TORCH): A Retrospective Multicenter Observational Study
Comparison of Endoscopic Band Ligation Plus 24-hour Versus 72-hour Terlipressin Therapy for the Control of Acute Variceal Bleeding in Patients With Liver Cirrhosis at a Tertiary Center in Mexico
Terlipressin vs. Somatostatin in Cirrhotic Patients With Acute Variceal Bleeding and Renal Dysfunction: A Multicenter Randomized Controlled Trial
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 78 citations in OpenAlex.
- Prophylactic antibiotics on patients with cirrhosis and upper gastrointestinal bleeding: A meta-analysis.PloS one · 2022Pooled it
- Treatment for bleeding oesophageal varices in people with decompensated liver cirrhosis: a network meta-analysis.The Cochrane database of systematic reviews · 2021Pooled it
- Comprehensive review on the current management of upper-GI bleed.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026Review
- Argon Plasma Coagulation as Rescue Endoscopic Hemostasis for Acute Variceal Bleeding in Cirrhosis: A Retrospective Cohort Comparison with Band Ligation.Medicina (Kaunas, Lithuania) · 2026Article
- A 13-year nationwide analysis of "the weekend effect" on outcomes of esophageal variceal bleed.Translational gastroenterology and hepatology · 2026Article
- Decline of the Sengstaken-Blakemore tube: A review of shifting practices in gastrointestinal hemorrhage management.World journal of critical care medicine · 2025Review
- Combining endoscopic variceal ligation and omeprazole sodium in treating upper gastrointestinal hemorrhage combined with liver cirrhosis.BMC gastroenterology · 2025Article
- Choosing Wisely: A Systematic Review of Terlipressin Versus Octreotide for Variceal Bleeding.Cureus · 2025Review
- Pharmacological Management for Prevention and Treatment of Posthepatectomy Liver Failure.Digestive surgery · 2025Review
- FDA-approved drugs featuring macrocycles or medium-sized rings.Archiv der Pharmazie · 2025Review
- Management of Portal Hypertension in the Older Patient.Current gastroenterology reports · 2024Review
- Real-world comparison of terlipressin vs. octreotide as an adjuvant treatment in the management of variceal bleeding.Scientific reports · 2024Review
- Guidelines for the Management of Esophagogastric Variceal Bleeding in Cirrhotic Portal Hypertension.Journal of clinical and translational hepatology · 2023Article
- Recent Approaches in Portal Hypertension Involving Risk Stratification and Medical Management.Gastroenterology & hepatology · 2023Article
- Continuous vs. intermittent terlipressin infusion for portal hypertension: a systematic review and meta-analysis.Annals of medicine and surgery (2012) · 2023Review
- Synthesis and clinical application of new drugs approved by FDA in 2022.Molecular biomedicine · 2023Review
- Terlipressin-Induced Skin Necrosis While Managing Hepatorenal Syndrome: A Rare Case Report From North India.Cureus · 2023Article
- Practice guidance for the use of terlipressin for liver cirrhosis-related complications.Therapeutic advances in gastroenterology · 2022Article
- Evidence-based clinical practice guidelines for Liver Cirrhosis 2020.Journal of gastroenterology · 2021Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimAcute variceal bleeding (AVB) is life-threatening. We aimed to systematically review the current evidence regarding the efficacy and safety of terlipressin for AVB in liver cirrhosis.
methodsWe searched the PubMed, EMBASE, and Cochrane Library databases. The reference list was also hand-searched. Using a random-effect model, we combined the data obtained according to the different time points when the events developed. Odds ratio (OR) and weighted mean difference (WMD) were calculated. Quality of evidence was evaluated by the GRADE methodology.
resultsThirty randomized controlled trials with 3344 patients were included. Compared with no vasoactive drug, terlipressin significantly improved the control of bleeding within 48 hours (OR = 2.94, P = .0008) and decreased the in-hospital mortality (OR = 0.31, P = .008). Compared with somatostatin, terlipressin had a significantly higher risk of complications (OR = 2.44, P = .04). Compared with octreotide, terlipressin had a significantly inferior control of bleeding within 24 hours (OR = 0.37, P = .007). Compared with vasopressin, terlipressin had a significantly lower risk of complications (OR = 0.15, P = .02). Compared with terlipressin combined with endoscopic variceal ligation, terlipressin alone had significantly higher 5-day treatment failure (OR = 14.46, P = .01) and transfusion requirements within 49 to 120 hours (WMD = 1.20, P = .002). No outcome was significantly different between terlipressin and sclerotherapy. Compared with balloon tamponade, terlipressin significantly decreased the 30-day rebleeding (OR = 0.05, P = .001) and transfusion requirements (WMD = -2.70, P = .02). Quality of evidence was very low to moderate.
conclusionOur findings were in accordance with the current recommendations regarding terlipressin for the treatment of AVB in cirrhosis. However, due to low quality of evidence, further studies are recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.